KKStock I have written several articles regarding the Glp-1 drugs, which I forecast to become the largest-selling pharmaceutical class ever, with 2030 US sales of $150 billion. The benefits of these drugs extend to lessening the chronic diseases associated with obesity that are responsible for significant healthcare spending. These include Type 2 diabetes, cardiovascular disease, obstructive sleep apnea, liver fibrosis, knee osteoarthritis, kidney disease, and possibly several CNS diseases. In fact, Novo No ...

Eli Lilly and Company’s (LLY) second-quarter 2024 results were exceptionally strong, beating estimates for earnings and sales.Moreover, adjusted earnings per share of $3.92 rose 86% year over year. Revenues of $11.3 billion rose 36% year over year.Strong demand for its successful GLP-1-based treatments, Mounjaro and Zepbound, and other key drugs, Verzenio and Taltz, pulled up the top line in the quarter. Almost all key drugs, Mounjaro, Zepbound, Taltz and Verzenio, beat expectations. Mounjaro and Zepbound t ...

How much upside could this juggernaut stock possibly have left?With shares of Eli Lilly (LLY 2.68%) temporarily jumping more than 10% on Aug. 8 following its earnings report for the second quarter, it's easy to conclude that the company's spate of good performance is destined to continue forever.But is there evidence to actually support that assertion, or is it a mirage masking an investment that's sure to burn investors who buy in right now? There's at least one argument in favor of each of those perspecti ...

Eli Lilly (LLY) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.The power of a c ...

The second-quarter earnings season has come to an end for large drug and biotech companies, with Eli Lilly (LLY) reporting its results last week. Per the Zacks classification, the pharma/biotech industry comes under the broader Medical sector, which comprises pharma/biotech as well as medical device companies.As of Aug 7, the Earnings Trends report showed that 85.7% of medical companies beat estimates for earnings and 75.5% beat the same for revenues. While earnings per share (EPS) rose 17.1% year over year ...

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?Let's take a look at what these Wall Street heavyweights have to say about Eli Lilly (LLY) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.Lilly currently has an average br ...

A large majority of the companies have already reported second-quarter results. While we can call it a mixed earnings season, there are a few companies that beat expectations and reported record revenue and profits. These earnings winners have proved their strength and are ready for a stellar second half of the year.I’ve identified three stocks that are on the rise after reporting impressive second-quarter results. These three companies have a lot of potential to keep the momentum going and their numbers pr ...

Mounjaro manufactured by Eli Lilly and Company packaging is seen in this illustration photo taken in ... [+] a pharmacy in Krakow, Poland on April 9, 2024. (Photo by Jakub Porzycki/NurPhoto via Getty Images)NurPhoto via Getty ImagesEli Lilly stock (NYSE: LLY) recently reported its Q2 results, with revenues and earnings exceeding the street expectations. The pharmaceutical giant reported sales of $11.3 billion and adjusted earnings of $3.92 per share, compared to the consensus estimates of $9.9 billion and $ ...

Lilly Seaport Innovation Center (LSC) serves as the central hub for Lilly's genetic medicines efforts and houses the first East Coast Lilly Gateway LabsNew 346,000 square foot facility will accommodate approximately 500 Lilly scientists and researchers, in addition to 200 people from Lilly Gateway Labs' companiesINDIANAPOLIS, Aug. 13, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the opening of the Lilly Seaport Innovation Center (LSC), a research and development facility in the Bos ...

A company's investments can easily ruin the plans of its competitors.Competitive dynamics matter, and often sooner than investors might expect. Eli Lilly's (LLY -0.82%) chief executive officer recently disclosed that the big pharma is positioned to cut off a potential driver of revenue growth for Hims & Hers Health (HIMS 0.06%), and that it will chalk up some growth itself along the way.Here's what's happening, and how it affects the case for an investment in each company.This blocker to revenue growth is r ...